Lineage Cell Therapeutics(NYSEMKT) LCTX

Lineage Cell Therapeutics, Inc. makes cells to replace damaged body parts. These treatments help people with vision and spinal cord injuries. The company grows replacement cells in large, lab-made batches.

Replacing Cells for Better Health

• OpRegen (RG6501): Allogeneic retinal pigment epithelium cell replacement therapy in Phase 2a testing for patients with severe vision loss.
• OPC1: Allogeneic nerve cell therapy in Phase 1/2a clinical trials for the treatment of cervical spinal cord injuries.
• ReSonance (ANP1): Allogeneic auditory neuron progenitor cell transplant currently in preclinical development for treating hearing loss.
• COR1: Allogeneic corneal endothelial cell therapy intended to treat vision loss caused by corneal diseases.

Strategic Partnerships and New Programs

• Achieved the first development milestone in the Roche collaboration in December 2025, resulting in a $5 million payment.
• Partnered with William Demant Invest in August 2025 to fund up to $12 million for hearing loss research.
• Launched the COR1 preclinical program in March 2026 to treat corneal endothelial disease using its existing manufacturing expertise.
• Started the ILT1 manufacturing initiative in September 2025 for potential diabetes applications.

Scalable Manufacturing in Action

Lineage utilizes a manufacturing platform called AlloSCOPE to produce scalable, off-the-shelf cell therapies. This system allows the company to grow thousands of doses from a single cell bank. The company conducts all manufacturing at its facility in Jerusalem, Israel.

Checking the Ledger

• Total revenues were $1.1 million for the three months ended June 30, 2026, down 61% year over year.
• Research and development expenses reached $4.8 million for the three months ended June 30, 2026, up 54% year over year.
• The company recorded total operating expenses of $10.0 million for the three months ended June 30, 2026, down 56% year over year.
• Cash, cash equivalents, and marketable securities totaled $50.8 million as of June 30, 2026.
• Net loss for the six-month period ended June 30, 2026, was $3.2 million.

Bottom Line

Lineage has transitioned from a general research entity to a clinical-stage developer focused on scalable cell manufacturing. Its reliance on partnerships and a shared technology platform allows it to target multiple serious medical conditions.